<SEC-DOCUMENT>0001178913-16-006112.txt : 20160808
<SEC-HEADER>0001178913-16-006112.hdr.sgml : 20160808
<ACCEPTANCE-DATETIME>20160808093702
ACCESSION NUMBER:		0001178913-16-006112
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20160808
FILED AS OF DATE:		20160808
DATE AS OF CHANGE:		20160808

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Check-Cap Ltd
		CENTRAL INDEX KEY:			0001610590
		STANDARD INDUSTRIAL CLASSIFICATION:	X-RAY APPARATUS & TUBES & RELATED IRRADIATION APPARATUS [3844]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			L3

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-36848
		FILM NUMBER:		161812990

	BUSINESS ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
		BUSINESS PHONE:		972-4-8303400

	MAIL ADDRESS:	
		STREET 1:		ABBA HUSHI AVENUE P.O. BOX 1271
		CITY:			ISFIYA
		STATE:			L3
		ZIP:			30090
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>zk1618832.htm
<DESCRIPTION>6-K
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/15.95pt 'Times New Roman', Times, serif">UNITED STATES</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/15.95pt 'Times New Roman', Times, serif">SECURITIES AND EXCHANGE COMMISSION</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">WASHINGTON, DC 20549</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; FONT: bold 14pt/13.7pt 'Times New Roman', Times, serif">FORM 6-K</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">REPORT OF FOREIGN PRIVATE ISSUER</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">PURSUANT TO RULE 13a-16 OR 15d-16 UNDER</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">THE SECURITIES EXCHANGE ACT OF 1934</div>

<div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">For&#160;August 2016</div>

<div style="LINE-HEIGHT: 13.7pt; FONT-WEIGHT: bold"><br style="LINE-HEIGHT: 13.7pt">
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Commission File No. 001-36848</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; MARGIN-LEFT: 0pt; MARGIN-RIGHT: 0pt"><font style="DISPLAY: inline; FONT-FAMILY: Times New Roman; FONT-SIZE: 16pt; FONT-WEIGHT: bold">Check-Cap Ltd. </font>

<div>
<hr style="TEXT-ALIGN: center; BACKGROUND-COLOR: #000000; HEIGHT: 2px; COLOR: #000000; MARGIN-LEFT: auto; MARGIN-RIGHT: auto" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">Check-Cap Building</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">Abba Hushi Avenue</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">P.O. Box 1271</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">Isfiya, 30090</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">Mount Carmel, Israel</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal">(ADDRESS OF PRINCIPAL EXECUTIVE OFFICES.)</div>
</div>

<div style="TEXT-ALIGN: center; TEXT-INDENT: 0pt; DISPLAY: block; FONT-FAMILY: times new roman; MARGIN-LEFT: 0pt; FONT-SIZE: 10pt; FONT-WEIGHT: bold; MARGIN-RIGHT: 0pt">&#160;</div>
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant files or will file annual reports under cover Form 20-F or Form 40-F.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 155pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Form 20-F &#9746;<font style="WIDTH: 9pt; DISPLAY: inline-block; FONT-SIZE: 1px">&#160;</font>Form 40-F &#9744;</div>

<div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1): ____</div>

<div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7): ____</div>

<div style="LINE-HEIGHT: 13.7pt"><br style="LINE-HEIGHT: 13.7pt">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Indicate by check mark whether the registrant by furnishing the information contained in this form is also thereby furnishing the information to the Commission pursuant to Rule 12g3-2(b) under the Securities Exchange Act of 1934.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; TEXT-INDENT: 175pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Yes &#9744;<font style="WIDTH: 9pt; DISPLAY: inline-block; FONT-SIZE: 1px">&#160;</font>No &#9746;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 13.7pt; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">If &#8220;Yes&#8221; marked, indicate below the file number assigned to the registrant in connection with Rule 12g3-2(b): 82-___</div>

<div style="LINE-HEIGHT: 13.7pt">&#160;</div>

<div style="LINE-HEIGHT: 13.7pt">
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">This Form 6-K is being incorporated by reference into the Post-Effective Amendment No. 1 to the Form S-8 Registration Statement File No. 333-203384<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"> and into the Form F-3 Registration Statement File No. 333-211065</font>.</div>

<div id="DSPFPageFooter">&#160;</div>
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div>&#160;</div>

<div>
<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">On August 8, 2016, Check-Cap Ltd. issued a press release announcing that it has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million. The Securities Purchase Agreement provides for gross proceeds of $5.9 million, which is comprised of 643,614 ordinary shares, at a purchase price of $1.90 per share and<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>2,514,281 pre-funded warrants <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">in </font>lieu of ordinary shares, at a purchase price of $1.85 per warrant, which are exercisable for a nominal exercise price (approximately $0.05 per share).&#160; In the event that all warrants are exercised, the total gross proceeds to the Company for this financing would be $6.0 million.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.</div>

<div id="DSPFPageFooter">&#160;</div>
</div>

<div>
<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Exhibits</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<table style="WIDTH: 100%; BORDER-COLLAPSE: collapse; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="za56b73b45c514a60a87c8dd58f5ee770" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 10.03%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">99.1</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</td>
<td style="WIDTH: 89.97%; VERTICAL-ALIGN: top">
<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Press Release, dated August 8, 2016.</div>
</td>
</tr>
</table>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 2px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">SIGNATURE</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Pursuant to the <font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">requirements of the&#160;Securities<font style="FONT-WEIGHT: bold">&#160;</font>Exchange Act of 1934, the<font style="FONT-WEIGHT: bold">&#160;</font>registrant<font style="FONT-WEIGHT: bold">&#160;</font></font>has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<table style="WIDTH: 100%; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" id="z32b6f456f94542bfaaaafd260852b620" border="0" cellspacing="0" cellpadding="0">
<tr>
<td style="WIDTH: 50%">
<div>&#160;</div>
</td>
<td style="WIDTH: 50%; FONT-FAMILY: 'Times New Roman', Times, serif">
<div style="FONT-WEIGHT: bold">Check-Cap Ltd.</div>

<div>&#160;</div>

<div>By:&#160; <font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: normal"><u>/s/ Lior Torem</u></font>_____</div>

<div>Name: Lior Torem</div>

<div>Title:&#160; Chief Financial Officer&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</div>

<div>&#160;</div>
</td>
</tr>
</table>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; MARGIN-RIGHT: 24pt">Dated: August 8, 2016</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto" align="center">
<br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99
<SEQUENCE>2
<FILENAME>exhibit_99-1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
<head>
<title></title>
<!--Licensed to: ZKG
    Document created using EDGARfilings PROfile 4.1.0.0
    Copyright 1995 - 2016 Summit Financial Printing, LLC.  All rights reserved.-->
</head>
<body style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt" bgcolor="#ffffff" text="#000000">
<div>
<hr style="BORDER-BOTTOM: black 1px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 4px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div id="DSPFPageHeader"></div>

<div style="TEXT-ALIGN: right; FONT: bold 10pt/1.25 'Times New Roman', Times, serif"><u>Exhibit 99.1</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25"><img style="WIDTH: 170px; HEIGHT: 72px" src="image0.jpg"></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold"><a id="_DV_M0" name="_DV_M0"></a><font style="FONT-VARIANT: normal; FONT-STYLE: normal; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 12pt; FONT-WEIGHT: bold">CHECK-CAP LTD. ANNOUNCES $5.9 MILLION FINANCING</font></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>ISFIYA, Israel, and BOSTON, August 8, 2016 - Check-Cap Ltd. (the &#8220;Company&#8221; or &#8220;Check-Cap&#8221;) (NASDAQ: CHEK, CHEKW), a clinical stage medical diagnostics company engaged in the development of an ingestible capsule for preparation-free, colorectal cancer screening, today announced that it has entered into an agreement with a single health-care focused institutional investor for a registered direct placement of $5.9 million.&#160; The Securities Purchase Agreement provides for gross proceeds of $5.9 million, which is comprised of 643,614 ordinary shares, at a purchase price of $1.90 per share and<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</font>2,514,281 pre-funded warrants in lieu of ordinary shares, at a purchase price of $1.85 per warrant, which are exercisable for a nominal exercise price (approximately $0.05 per share).&#160; In the event that all warrants are exercised, the total gross proceeds to the Company for this financing would be $6.0 million.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The Company intends to use the net proceeds from the offering to advance the ongoing clinical development of its preparation-free, less-invasive colorectal cancer screening system, and for general corporate purposes.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The placement is expected to close on or before August 11, 2016, subject to satisfaction of customary closing conditions.</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The ordinary shares and pre-paid warrants and the ordinary shares underlying the pre-paid warrants are being offered pursuant to a shelf registration statement (File No. 333-211065), which was declared effective by the United States Securities and Exchange Commission ("SEC") on July 11, 2016.&#160; A prospectus supplement relating to the offering will be filed with the SEC.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="LINE-HEIGHT: 1.25">
<div id="DSPFPageHeader"></div>

<div style="LINE-HEIGHT: 1.25">Chardan Capital Markets, LLC acted as the exclusive placement agent for the offering. Maxim Group LLC <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">and Roth Capital Partners </font>acted as financial <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">advisors</font> to the transaction.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">About Check-Cap</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Check-Cap is a clinical-stage medical diagnostics company developing the world&#8217;s first ingestible capsule system for preparation-free, less-invasive colorectal cancer screening.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">The capsule utilizes innovative ultra-low dose X-ray and wireless communication technologies to scan the inside of the colon as it moves naturally, while the patient follows his or her normal daily routine.&#160;&#160; After passage, the system generates a 3D map of the inner surface of the colon which enables detection of polyps and cancer.&#160; Designed to increase the willingness of individuals to participate in recommended colorectal cancer screening, the Check-Cap system addresses many frequently-cited barriers, including laxative bowel preparation, invasiveness, and sedation. The Check-Cap system is currently not cleared for marketing in any jurisdiction.</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="MARGIN-TOP: 10pt; MARGIN-BOTTOM: 10pt; CLEAR: both" id="DSPFPageBreakArea">
<div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
<hr style="BORDER-RIGHT-WIDTH: 0px; BACKGROUND-COLOR: #000000; MARGIN: 4px 0px; WIDTH: 100%; BORDER-TOP-WIDTH: 0px; BORDER-BOTTOM-WIDTH: 0px; HEIGHT: 3px; COLOR: #000000; CLEAR: both; BORDER-LEFT-WIDTH: 0px" noshade="noshade">
</div>
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">Legal Notice Regarding Forward-Looking Statements</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: justify; LINE-HEIGHT: 1.25; FONT-STYLE: italic; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">This press release contains &#8220;forward-looking statements.&#8221; Words such as &#8220;may,&#8221; &#8220;should,&#8221; &#8220;could,&#8221; &#8220;would,&#8221; &#8220;predicts,&#8221; &#8220;potential,&#8221; &#8220;continue,&#8221; &#8220;expects,&#8221; &#8220;anticipates,&#8221; &#8220;future,&#8221; &#8220;intends,&#8221; &#8220;plans,&#8221; &#8220;believes,&#8221; &#8220;estimates,&#8221; and similar expressions, as well as statements in future tense, often signify forward-looking statements. Forward-looking statements should not be read as a guarantee of future performance or results and may not be accurate indications of when such performance or results will be achieved. Forward-looking statements are based on information that the Company has when those statements are made or management&#8217;s good faith belief as of that time with respect to future events, and are subject to risks and uncertainties that could cause actual performance or results to differ materially from those expressed in or suggested by the forward-looking statements. For a discussion of these and other risks that could cause such differences and that may affect the realization of forward-looking statements, please refer to the &#8220;Special Note On Forward-looking Statements&#8221; and &#8220;Risk Factors&#8221; in the Company&#8217;s Annual Report on Form 20-F and other filings with the Securities and Exchange Commission (SEC). Investors and security holders are urged to read these documents free of charge on the SEC&#8217;s web site at <font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>http://www.sec.gov</u></font>. The Company assumes no obligation to publicly update or revise its forward-looking statements as a result of new information, future events or otherwise.</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"># # #</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt; FONT-WEIGHT: bold">CONTACT:</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Investors</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">David Carey</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Lazar Partners Ltd.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">212-867-1768</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>dcarey@lazarpartners.com</u></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Vivian Cervantes</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">PCG Advisory<font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><br>
</font> 212-554-5482</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>vivian@pcgadvisory.com</u></div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>Media</u></div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Erich Sandoval</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">Lazar Partners Ltd.</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">213-908-6226</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><font style="FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"><u>esandoval@lazarpartners.com</u></font> &#160;</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">&#160;</div>

<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">2</div>

<div style="TEXT-ALIGN: left; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt">
<hr style="BORDER-BOTTOM: black 4px solid; TEXT-ALIGN: center; BACKGROUND-COLOR: #ffffff; HEIGHT: 10px; COLOR: #ffffff; MARGIN-LEFT: auto; BORDER-TOP: black 1px solid; MARGIN-RIGHT: auto" align="center">
</div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>

<div style="LINE-HEIGHT: 1.25">&#160;</div>

<div id="DSPFPageFooter">
<div style="TEXT-ALIGN: center; LINE-HEIGHT: 1.25; FONT-FAMILY: 'Times New Roman', Times, serif; FONT-SIZE: 10pt"></div>

<div style="LINE-HEIGHT: 1.25"><br style="LINE-HEIGHT: 1.25">
</div>
</div>
</body>
</html>

</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>image0.jpg
<TEXT>
begin 644 image0.jpg
M_]C_X  02D9)1@ ! 0$ 8 !@  #_VP!#  @&!@<&!0@'!P<)"0@*#!0-# L+
M#!D2$P\4'1H?'AT:'!P@)"XG("(L(QP<*#<I+# Q-#0T'R<Y/3@R/"XS-#+_
MVP!# 0D)"0P+#!@-#1@R(1PA,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C(R
M,C(R,C(R,C(R,C(R,C(R,C(R,C(R,C+_P  1" !) *L# 2(  A$! Q$!_\0
M'P   04! 0$! 0$           $" P0%!@<("0H+_\0 M1   @$# P($ P4%
M! 0   %] 0(#  01!1(A,4$&$U%A!R)Q%#*!D:$((T*QP152T? D,V)R@@D*
M%A<8&1HE)B<H*2HT-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U
M=G=X>7J#A(6&AXB)BI*3E)66EYB9FJ*CI*6FIZBIJK*SM+6VM[BYNL+#Q,7&
MQ\C)RM+3U-76U]C9VN'BX^3EYN?HZ>KQ\O/T]?;W^/GZ_\0 'P$  P$! 0$!
M 0$! 0        $" P0%!@<("0H+_\0 M1$  @$"! 0#! <%! 0  0)W  $"
M Q$$!2$Q!A)!40=A<1,B,H$(%$*1H;'!"2,S4O 58G+1"A8D-.$E\1<8&1HF
M)R@I*C4V-S@Y.D-$149'2$E*4U155E=865IC9&5F9VAI:G-T=79W>'EZ@H.$
MA8:'B(F*DI.4E9:7F)F:HJ.DI::GJ*FJLK.TM;:WN+FZPL/$Q<;'R,G*TM/4
MU=;7V-G:XN/DY>;GZ.GJ\O/T]?;W^/GZ_]H # ,!  (1 Q$ /P#W^BBN&^(G
MQ%M/!-DL,2K<ZM.N88">$']]_;V[U48N;Y8B;25V=;J6JZ?H]HUUJ-Y!:P+U
M>9PH_7K7!ZA\;_"%G(R027EZ1_%!!A3^+$5\]:WKVJ>(]0:]U:\DN9B>-Q^5
M!Z*O11]*S:]&&!BE[[.66(?V3Z'_ .%^^'/^@;J?_?"?_%4?\+]\.?\ 0-U/
M_OA/_BJ^>**T^I4B/;S/H?\ X7[X<_Z!NI_]\)_\51_POWPY_P! W4_^^$_^
M*KYXHH^I4@^L3/H?_A?OAS_H&ZG_ -\)_P#%4?\ "_?#G_0-U/\ [X3_ .*K
MYXHH^I4@^L3/H?\ X7[X<_Z!NI_]\)_\51_POWPY_P! W4_^^$_^*KYXHH^I
M4@^L3/H?_A?OAS_H&ZG_ -\)_P#%4?\ "_?#G_0-U/\ [X3_ .*KYXHZG !)
M]!1]2I![>9](:?\ &[1M4U""PL=&U:>ZG?9'&J)DG_OKI[UZ<I)4%AM)'(]*
M\W^$_P /E\+Z4NJ:C$/[8NTR0PYMXST0>Y[_ )=J['4M0.3;PM[.P_D*\VM[
M-2M#8ZX<UKR+,VK6\4A0!GQU*]*1=8MB>1(OU%8-%9%G4Q7$4XS%(K?0U+7)
M*S(P9&*L.A!K;T_4O.(AFP).S?WO_KT :5%%% &9X@UJW\/:#>ZM=']U;1%R
M.['LH]R<#\:^0=9U>\U[6+K5+^0O<W#EV/9?11[ <"O<?C]JS0:!IFE(V/M<
MYED'JJ#C]6'Y5X!7J8*FE#G[G'B)W?*=IX*\"#Q';3:GJ-V;/2H"09!@%R.N
M"> !W-:&O>$?" \/WVH>']=,]Q9IO:$RJ^X9 ] >_49J]>I++\!['[""8TE!
MN@GH';.?;.W->7JCR!S&C-M4LVT9PO<GVK2'/4DY<UK/83Y8I*QUOBOPK8Z'
MX;T+4;66=YM0CW2B1@5!V@\8'O1:>%K&?X9WOB1Y9Q>03&-4##RR-RCD8SW/
M>O0=5G\+P>#?#9\3V\LT9ME\@1AC@[%ST(]JIZO+H4WP?U1_#L,D-AYH&UP0
M=^]<]2?:LE6G9+7??YE>SC=OR,UO _@S3]%TR]UG5[RT:]A5U^88+;03C"GU
MKF'\,66L>,DT?PO>-<V;(KFYE_@&/G)X'3Z5Z'KM[X9L_"?AL^)+":[1K9?(
M$>?E.Q<]Q[5G_#NXT>Y\9:Y)H5NUM;M9I]FCD^\N#\W<]\=Z4:DU%SU_0;A%
MM(CD\ >!;6<:9=>(W34ONG=.BX;_ '<8'T)KG],\%6%QI/BJXN+F=IM'=TA:
M,@*^T$Y(P?3L:XR]2>/4+B.[5A="5A*'^]OSSG\:]1^&1@M?"GB4ZG$_V>)U
M-Q&P^;:$.016D^>G#FYK[$QY92M:QS>H>$;#1? -KJ^I2W"ZM>D?9[=6 4 \
M@L,9X7D_45Q=>G?%^TNIKG3-6CE$VE20B.'9]V-CS_X\,8^E>8UM0DY0YF]S
M.JDI605Z?\&/!HUW7VUF]CW6&G,"BL.))NH'T7K]<5YE'&\TJ11*7D=@J*.I
M)X KZ]\'^'X?"?A*RTP8#0Q[YW'\4AY8_G^@%98NKR0LMV50AS2NS1U.\^SP
M[$/[Q_T'K6!4MQ.UQ</*>YX'H*BKQSN"BBB@ H!(.1P1THHH Z2PN?M5L&/W
MUX;ZU:K"T:0K=-'V=?U%;M,#P']H(M_;NB@_=^RR8^NX9_I7CU>]?M :6TND
MZ1JJ+D6\SP2'T#@$?JOZUX+7LX1WI(X*Z]]G8>#/'EQX526TFMA>:=,VYH<X
M*,>"5SQSW!K4U_XB:5=Z%>:7HN@)9"\39-*0JG'7@+U/U->=T5;H0<N:VI*J
M22L=5XF\60:]X?T738K26%].CV.[L"'^4#C'THM?%D%O\.[SPR;64S3RF03A
MAM'*G&.O:N5HI^RC:WS#G=[GIT?Q(\/S:1I]EJ7AM[TV<*QJ9"A (4 D9Z9Q
M7-7/BV*T\7QZYX>L$TZ..-4^S$#:W'S X[&N6HI1H0CL#J29ZP_Q6T.1EO9/
M# ?4E'$C;#@_[V,USEAX[C@TWQ+#<V3M/K3LX:-P%C+ COR>M<5126'IK8;J
MR9VND>.+:+P9<>&M:L9KRW8$021N T0ZCKZ'D?E7%5ZE\)].\'>)'ET;7-*C
M?4US)!-YKKYR=UP#C</U'TK1^*_PPL=#TJ/6_#UJ8;:'Y+N ,S8!/$@R2>O!
M^HJ(U80J.%K7*<)2AS',?"#0QK7Q M'D3=!8*;I_3(X3_P >(/X5]):O-Y=J
M(P>9#@_2O+/V?]+$>CZMJK+\T\ZP(W^R@R?U;]*]%U63S+_9V0 5P8N?-5:[
M'10C:!YUXK^(4>A:FNDZ=8-J.I$ O&I.$SR!P"2<<X%)H7Q DO;;56U?2)M/
METVW^TR*,_,N<<!@#FLCX?!)_B#XJN;C!O4D8)NZJI<@X_)17H.K#3QIEW-J
M:QFT6$^>SCK&.2#[<=*)J$+0Y=>XXN4O>N>=+\6[V.2.YN_#<L6ER-A9MS;L
M>Q(VD^U=/XO\8_\ "-Z)8ZG:6T=Y'=R!4W.5&TKN!XKC?&'B75?$W@RYN+32
M4M?#Z2(%GG;]Y*0V!L4< 9I/''_),?"?UB_]%UK[*#<=+:V(YY)/4T(/BU-;
MSQC6O#MQ9P.<>:I;(]\,!G\#7I5O<0W=M%<V\BR0RH'1UZ,#T-8/C:*WG\!:
MF+H*42UWH6_A< ;2/?-5/AF\C^ --\W/!D"Y_N[SBL*BA*'/%6UL:1<E+E;N
M=QIG_(0B_'^5='6#H\9:\+]D7^=;U8&AC^*= A\3^&K[2)R%%Q'A'_N..5;\
M"!7R#J%A=:5J-Q87L1BN;>0QR(>Q']*^UJ\X^)GPSC\7P_VCIVR'68EP"W"W
M"CHK'L?0_@?;KPM=4WRRV9A6I\RNMSYGHJS?Z?>:5>R65_;2VUS&</%*N"/\
M1[U6KUD[['$U8****8!1110 4444 6+&^N=,O[>^LY3%<V\@DB<=F%?6GAK6
M['QSX.BO&C5HKJ(PW4!Y"MC#J?\ /0BOD.O5/@=XF.F^)9=#G?%MJ*YC!/"S
M*./S&1^ KDQ=+FAS+=&]"=G9]3VCP1X9'A'PXNDB02!)Y7#_ -Y6<E<^^W%0
MW+^9=2OZN:Z@G"D^@KDR<DGU->3)N3NSL2LK'GGB?P+JK>(3XA\+7JVM])_K
MHV?9N/0D'ISW!HL/"_B[5+/58?$^JHR7=H8(8T<,(WR"&(4 =OK7H5%:^WG:
MQ/LU>YY/_P (9XYN?";>'I[G3H[&#F% V6EPV0N[' SD\U1\9Z?K.F?#_2+3
M69H&GCO D*0](HQ'@ GN>Y->S5S_ (M\*Q>++&VM9;N2V$$WFAD0,3QC'-:0
MQ+YES;$2I::'&S^#O'/B%(;'7=;@&F*58F,@LX'3@ 9/UKTJPLK?3=/M[&U3
M9! @CC7V']:G1<*J#G  'O6SI^F%6$TXY'*H>WN:QJ593T>Q<8*):TVV-M;?
M,/G?YF]O:KE%%9EA1110!D:[X8T7Q+;"#5]/ANE'W688=/HPY'YUYU?_  !T
M.>0M8:I?6BG^!PLH'YX/ZUZY16D*LX?"R90C+='BG_#/5OGGQ'-_X"C_ .*I
M?^&>K7_H8Y__  %7_P"*KVJBM/K5;N3[&'8\5_X9ZM?^ACG_ / 5?_BJ/^&>
MK7_H8Y__  %7_P"*KVJBCZU6[A[&'8\5_P"&>K7_ *&.?_P%7_XJC_AGJU_Z
M&.?_ ,!5_P#BJ]JHH^M5NX>QAV/%?^&>K7_H8Y__  %7_P"*JS8? >/3M1MK
MZW\2W"S6TJRH?LR]5.?[U>PT4GB:KZA[*'80C<I'J,5E?V(O_/=O^^:UJ*P-
M#)_L1?\ GNW_ 'S1_8B_\]V_[YK6HH R?[$7_GNW_?-.71(P?FF<CV %:E%
6%>"R@MN8XQN_O'DU8HHH **** /_V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
